MAPT and Alzheimer disease: Conventional treatment options targeting the Aβ plaques and tau tangles are merely relieving symptoms for mild and moderate AD patients, which are not able to alleviate brain damages caused by oxidative stress and neuroinflammation, frequently observed in a severe AD stage [109,126].